Literature DB >> 14703193

Basic mechanisms and clinical implications of peritoneal fibrosis.

Peter J Margetts1, Philippe Bonniaud.   

Abstract

We have stressed the role of certain growth factors and cytokines in peritoneal fibrosis, including TGFbeta, TIMP-1, and inflammatory cytokines, especially IL-1beta. Recent research highlights the myofibroblast-like transformation of mesothelial cells as a central initiating event in peritoneal fibrosis. The induction, survival, and apoptosis of the myofibroblast cell population likely dictate the nature of the fibrogenic response. The accumulation of collagen occurs in a nondegradative environment, and collagenases and their inhibitors have a role in the maintenance of fibrosis. Fibrosis appears to be a ubiquitous response of peritoneal tissues to the damaging effects of uremia, bioincompatible dialysate, recurrent infection, and inflammation. Recent research has focused on the induction of angiogenesis, as this appears to correlate with increased solute transport and peritoneal membrane ultrafiltration failure. Fibrosis may play an integral part in peritoneal membrane dysfunction in several aspects. Angiogenesis may be induced as part of the fibrotic response, as many key fibrogenic cytokines are also strongly angiogenic. Fibrotic tissue may support and preserve angiogenesis. Changes in the interstitium may have a direct effect on the hydrodynamic properties of the peritoneum and may directly influence fluid movement. In its most extreme form, fibrosis manifests as the rare but devastating EPS. Peritoneal biopsy studies have identified a high prevalence of peritoneal fibrosis in PD patients. Research into peritoneal fibrosis will be enhanced by new animal models where the role of various cytokines and growth factors, cellular processes, and matrix interactions can be studied. With these models, the role of fibrosis in alteration of peritoneal membrane function can be better assessed. Clinical trials to assess the role of prevention of peritoneal injury using biocompatible solutions and treatments targeted directly at peritoneal fibrosis will be important, but challenging to design and carry out.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14703193

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  46 in total

1.  The Therapeutic Potential of Human Umbilical Mesenchymal Stem Cells From Wharton's Jelly in the Treatment of Rat Peritoneal Dialysis-Induced Fibrosis.

Authors:  Yu-Pei Fan; Ching-Chih Hsia; Kuang-Wen Tseng; Chih-Kai Liao; Tz-Win Fu; Tsui-Ling Ko; Mei-Miao Chiu; Yang-Hsin Shih; Pei-Yu Huang; Yi-Chia Chiang; Chih-Ching Yang; Yu-Show Fu
Journal:  Stem Cells Transl Med       Date:  2015-12-30       Impact factor: 6.940

2.  miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2.

Authors:  Marta Fierro-Fernández; Óscar Busnadiego; Pilar Sandoval; Cristina Espinosa-Díez; Eva Blanco-Ruiz; Macarena Rodríguez; Héctor Pian; Ricardo Ramos; Manuel López-Cabrera; Maria Laura García-Bermejo; Santiago Lamas
Journal:  EMBO Rep       Date:  2015-08-27       Impact factor: 8.807

Review 3.  Transition of mesothelial cell to fibroblast in peritoneal dialysis: EMT, stem cell or bystander?

Authors:  Yu Liu; Zheng Dong; Hong Liu; Jiefu Zhu; Fuyou Liu; Guochun Chen
Journal:  Perit Dial Int       Date:  2015 Jan-Feb       Impact factor: 1.756

4.  TGF-β₁-siRNA delivery with nanoparticles inhibits peritoneal fibrosis.

Authors:  H Yoshizawa; Y Morishita; M Watanabe; K Ishibashi; S Muto; E Kusano; D Nagata
Journal:  Gene Ther       Date:  2015-01-08       Impact factor: 5.250

5.  Peritoneal Dialysis Catheter Increases Leukocyte Recruitment in the Mouse Parietal Peritoneum Microcirculation and Causes Fibrosis.

Authors:  Paulina M Kowalewska; Peter J Margetts; Alison E Fox-Robichaud
Journal:  Perit Dial Int       Date:  2015-10-16       Impact factor: 1.756

6.  Differentiation of bone marrow-derived cells into regenerated mesothelial cells in peritoneal remodeling using a peritoneal fibrosis mouse model.

Authors:  Yoshimi Sekiguchi; Chieko Hamada; Yuuki Ro; Hirotaka Nakamoto; Masanori Inaba; Tetsutaro Shimaoka; Hiroaki Io; Ichiro Koyanagi; Seiki Aruga; Jiro Inuma; Kayo Kaneko; Yoko Hotta; Peter J Margetts; Hideki Mochizuki; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Artif Organs       Date:  2012-05-24       Impact factor: 1.731

7.  Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice.

Authors:  Hiroyuki Kadoya; Minoru Satoh; Hajime Nagasu; Tamaki Sasaki; Naoki Kashihara
Journal:  Clin Exp Nephrol       Date:  2014-09-13       Impact factor: 2.801

8.  Influence of bicarbonate/low-GDP peritoneal dialysis fluid (BicaVera) on in vitro and ex vivo epithelial-to-mesenchymal transition of mesothelial cells.

Authors:  Antonio Fernández-Perpén; María Luisa Pérez-Lozano; María-Auxiliadora Bajo; Patricia Albar-Vizcaino; Pilar Sandoval Correa; Gloria del Peso; María-José Castro; Abelardo Aguilera; Marta Ossorio; Mirjam E Peter; Jutta Passlick-Deetjen; Luiz S Aroeira; Rafael Selgas; Manuel López-Cabrera; J Antonio Sánchez-Tomero
Journal:  Perit Dial Int       Date:  2012-01-03       Impact factor: 1.756

9.  Heme oxygenase-1 attenuates epithelial-to-mesenchymal transition of human peritoneal mesothelial cells.

Authors:  Kitae Bang; Jinuk Jeong; Jong Ho Shin; Ju Hyung Kang; Chang Nam Kim; Hye-Jung Yeom; Myeong Ok Yoon; Jaeseok Yang; Curie Ahn; Jong-Ik Hwang; Mee Young Park; Joo-Heon Kim; Kang Wook Lee
Journal:  Clin Exp Nephrol       Date:  2012-11-14       Impact factor: 2.801

10.  Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology.

Authors:  Kazuho Honda; Chieko Hamada; Masaaki Nakayama; Masanobu Miyazaki; Ali M Sherif; Takashi Harada; Hiroshi Hirano
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-13       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.